Contineum Therapeutics Inc. has released its first-quarter 2025 financial results, reporting a net loss of $16.0 million, a significant increase from the $8.4 million net loss in the same quarter of the previous year. This increase is primarily attributed to a substantial rise in research and development expenses, which totaled $13.7 million, reflecting a 76 percent increase from the first quarter of 2024. The rise in expenses is largely due to the advancement of the company's PIPE-791 and PIPE-307 programs, as well as higher employee-related costs. General and administrative expenses also saw an uptick, reaching $4.4 million, up by $2.2 million compared to the first quarter of 2024. This increase was mainly driven by higher stock-based compensation expense and employee-related costs. Contineum Therapeutics remains on track with its key clinical development milestones. The company expects to report topline data from the PIPE-791 Phase 1b PET trial in the second quarter of 2025 and anticipates topline data from the PIPE-307 Phase 2 VISTA trial for relapsing-remitting multiple sclerosis in the second half of 2025. The company has completed the chronic toxicity studies for PIPE-791, supporting future Phase 2 trials, and plans to initiate Phase 2 proof-of-concept clinical trials in idiopathic pulmonary fibrosis and progressive multiple sclerosis in the latter half of 2025. With a cash runway projected through 2027, Contineum Therapeutics is focused on executing its clinical development objectives, driven by its vision of developing new therapies for patients with limited treatment options.